On August 5, AKESO rose 3.04% in regular trading, trading at 96.6 HKD/share, with turnover of HKD 392 million. The gain was primarily driven by broad-based strength across the innovative drug sector.

On the news front, the innovative drug sector saw collective gains, with peers including Innovent Bio up 4.96%, BeiGene up 3.25%, and KEYMED Bio up 3.94%. The sector is being catalyzed by expectations of key clinical data disclosures at major academic conferences scheduled for the second half, including WCLC, ESMO, and ASH, which are drawing investor attention back to pipeline readouts and commercialization progress.

Supporting the broader positive sentiment, AKESO's global partner Summit recently updated overall survival data from the Phase III HARMONi study for ivonescimab, showing the hazard ratio improved to 0.76 in Western patients, substantively validating cross-ethnic efficacy consistency. The company also initiated first-patient dosing in a Phase II trial combining its novel Trop2/Nectin-4 bispecific ADC (AK146D1) with ivonescimab for advanced NSCLC, further expanding its pipeline depth.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)